Objective: Vitamin A supplementation to mothers in the postpartum period and to their infants at routine immunization contacts is being considered to reduce vitamin A deficiency in infancy. This study was conducted to determine the impact of maternal and infant vitamin A supplementation on antibody response to oral polio vaccine (OPV). Design: Randomized, double blind, placebo-controlled trial. Interventions: Mothers in the intervention group received 60 mg retinol equivalent (RE) vitamin A 3 -4 weeks after delivery and their infants 7.5 mg RE with each OPV dose at 6, 10 and 14 weeks of age. The control group mothers and their infants received a placebo at each of these contacts. Main outcomes: Geometric mean (GM) titer of neutralizing antibodies and proportion of children with protective titer to the three polioviruses at 26 weeks of age. Results: Vitamin A supplementation increased the proportion of infants with protective antibody titer against poliovirus type 1 (relative risk (RR) 1.15, 95% confidence interval (CI) 1.03 -1.28) and the GM antibody titer (ratio of GM 1.55, 95% CI 1.03 -2.31) following immunization. The proportion of infants with protective antibody titer against poliovirus type 2 (RR 0.99, 95% CI 0.94 -1.05) or type 3 (RR 1.05, 95% CI 0.96 -1.15) was not significantly different in vitamin A and placebo groups. The GM antibody titer for poliovirus type 2 (ratio of GM 0.99, 95% CI 0.64 -1.54) or poliovirus type 3 (ratio of GM 1.10, 95% CI 0.69 -1.75) also did not differ across groups. Conclusions: Vitamin A given to the mothers in the postpartum period and their infants with OPV did not interfere with the antibody response to any of the three polioviruses and enhanced the response to poliovirus type 1.
Introduction
The current strategy in most developing countries for preventing vitamin A deficiency is high dose supplementation at 4 -6 month intervals after the age of 6 months. The first feasible opportunity to administer vitamin A in public health programs is with measles immunization at 9 months of age. In some countries, however, a significant proportion of children develop sub-clinical vitamin A deficiency as early as 6 months of age. Administration of 60 mg retinal equivalent (RE) vitamin A to the mother in the postpartum period and 7.5 mg RE vitamin A to the infant with each of the three doses of diphtheria pertussis tetanus vaccine (DPT) and oral polio vaccine (OPV) at 6, 10 and 14 weeks of age is a possible strategy to combat early vitamin A deficiency (World Health Organization (1994) policy document). It is important to determine the impact of such an intervention on immune response to the co-administered vaccines.
Few studies have examined the impact of vitamin A supplementation on concurrently administered vaccines in humans, particularly in infants. These studies showed variable results; in some vitamin A supplementation enhanced the antibody response to diphtheria and measles vaccines (Benn et al, 1997; Bhaskaram & Rao, 1997; Rahman et al, 1999) , while in others there was no benefit when given with measles and OPV (Semba et al, 1997 (Semba et al, , 1999 Bahl et al, 1999) or reduced seroconversion to measles vaccine (Semba et al, 1995) . In the last mentioned study, the authors hypothesized that immune stimulation by vitamin A limited the take-up of the live measles vaccine virus, particularly in infants with maternal antibodies.
We therefore conducted a randomized, double-blind, placebo controlled trial in New Delhi, India, to evaluate the impact of maternal and Expanded Program on Immunization (EPI)-linked vitamin A supplementation on the antibody response to OPV. This study was part of a multicenter study of maternal and EPI-linked vitamin A supplementation conducted in India. Ghana and Peru, which evaluated the impact of supplementation on vitamin A status and morbidity (WHO=CHD Immunization-Linked Vitamin A Supplementation Study Group, 1998) .
Methods

Study site
The study was conducted in the urban slums of Tigri-Dakshinpuri in south Delhi. In this setting, over half of under-5-y-old children were stunted and about 20% wasted. In children aged 1 -5 y seeking care at an outpatient clinic in a neighboring slum, the prevalence of clinical vitamin A deficiency was about 3.5% and that of sub-clinical vitamin A deficiency (serum vitamin A 0.7 mmol=l) was 37% (Bhandari et al, 1994) .
Sample size
The sample size to detect a 15% change in the proportion of infants with protective neutralizing antibody titres against polioviruses after three OPV doses in the vitamin A group with 90% power and 95% confidence was estimated to be 178 infants per group, assuming the proportion in controls to be 82% (World Health Organization, 1993) . To allow for slightly different control values in our population and about 20% dropouts for the second blood sample, we enrolled a total of 526 infants.
Study interventions
Newborns were identified in the community through a household survey. Families not intending to stay in the area were excluded. The study purpose and procedures were explained in the local language and written consent obtained.
In the vitamin A group, mothers were administered 60 mg RE vitamin A 18 -28 days post-partum and their infants received 7.5 mg RE vitamin A at 6, 10 and 14 weeks of age with each of the three doses of OPV and DPT.
Enrollment commenced in February 1996 and the last follow-up was completed in May 1997. The study was approved by the All India Institute of Medical Sciences ethics committee.
Randomization, labeling and masking
Using random permuted block size of eight, mother -infant pairs were allocated to vitamin A and placebo group. Vitamin A was provided as retinol palmitate with minute amounts of vitamin E; placebo was soybean oil. Identical opaque gelatin capsules containing vitamin A and placebo were packaged in individually coded blister packs. Back-up capsules were administered if the child vomited within 15 min of receiving a scheduled dose.
Immunization and follow-up
Infants were administered OPV and DPT vaccines within 20 min of supplementation at 6, 10 and 14 weeks of age. A single lot of OPV obtained directly from Panacea Biotec Ltd, Delhi, was used for the study. The tissue culture dose 50% infectivity (TCID 50 ) in each dose of the vaccine was 10 6 for poliovirus type 1, 10 5 for type 2 and 10 5.5 for type 3. The vaccine was stored at 7 20 C and daily requirements were transported to the field clinics in vaccine carriers. The temperature of the freezer was monitored twice daily throughout the study period.
Weights (Salter scale, sensitivity 0.1 kg) and lengths (locally manufactured length boards, sensitivity 0.1 cm) were measured in all infants. Infants were visited at home 24 and 48 h after each supplementation to monitor potential adverse effects including examination for bulging of anterior fontanelle. The fontanelle was always examined with the infant in an upright position and when quiet.
Laboratory tests
About 3 ml venous blood was obtained from each infant at baseline and 12 weeks after the third dose of OPV. Among the 526 enrolled infants, the pre-immunization blood sample could be obtained in 461 (88%) and the post-immunization sample in 410 (78%) infants. The dropout rate was similar in the two study groups. The baseline characteristics of those in whom the serum sample was obtained were similar to those in whom it was not available.
Serum was separated by centrifugation within 30 -45 min and transferred into a previously labeled cryotube. The tube was covered with aluminium foil and stored at 2 -8 C until transportation to the central laboratory the same day, where it was stored at 7 20 C until analysis. Neutralization assays were performed to estimate antibodies against poliovirus types 1, 2 and 3 in the postimmunization samples. Poliovirus type 2 antibodies . Then 32 -316 (10 2 AE 0.5 ) TCID 50 of poliovirus type 1, 2 or 3 diluted with 50 ml of incubation medium was added to each well and incubated at 37 C for 3 h. After incubation, 50 ml of Vero cells (50 000 cells=ml) suspended in an incubation medium were added to each well. The plates were sealed and incubated at 35 C for 7 days. Microscopic examination was performed on day 7 for presence or absence of cytopathogenic effect. Serum with a high titer of neutralizing antibodies inhibited the cytopathogenic effect of the poliovirus at a high dilution, while serum with no antibody failed to do so. Cell quality controls, virus controls and standard serum controls were tested in each plate.
Analysis
Analysis was performed on an intention-to-treat basis using EPI INFO version 6.04 and SPSS for Windows version 8.0 software. A post vaccination serum antibody titer ! 4 was considered to be protective.
Categorical variables were compared using the w 2 test while quantitative outcomes were compared by Student's ttest. Tests were two-sided and differences were considered significant at P-values < 0.05.
Results
The baseline characteristics including rates of prematurity and low birth weight in infants included in the analysis were similar in the vitamin A and placebo groups (Table 1) .
Almost all (99.6%) infants had maternally acquired antibody to poliovirus type 2 at baseline.
Overall, 76.4, 92.7 and 82.4% infants had protective titers against poliovirus type 1, 2 and 3 respectively, 12 weeks after the third dose of OPV. The proportion of infants with protective titer against poliovirus type 1 was significantly higher in the vitamin A group (82 vs 71.2%, relative risk (RR) 1.15, 95% confidence interval (CI) 1.03 -1.28). The geometric mean (GM) poliovirus type 1 antibody titers were also significantly higher in the vitamin A group (ratio of GM 1.55, 95% CI 1.03 -2.31). There were no statistically significant differences between the vitamin A and placebo groups in the GM titers and the proportion of infants with protective antibody titer against poliovirus types 2 or 3 ( Table 2) .
Vitamin A status was measured in a random sample of Indian infants in the multi-center study, of which the current study was a part, at 6 weeks and 6 months of age (WHO=CHD Immunization Linked Vitamin A Supplementation Study Group, 1998) . The mean serum retinol (0.57 (s.d. 0.24) and 0.55 (s.d. 0.23) and the proportion of infants with serum retinol < 0.7 mmol=l (76.5 and 81.1%) were similar in the vitamin A and placebo groups. Maternal and infant supplementation improved mean serum retinol (difference in means 0.1 mmol=l, 95% CI 0.001 -0.19) and reduced the proportion with serum retinol 0.7 mmol=l (difference in proportions 7 10.2%, 95% CI 7 23 -2.6%), and low vitamin A status as indicated by Modified Relative Dose Response (MRDR) > 0.06 (difference in proportions 7 13%, 95% CI 7 25.8 to 7 0.3%).
Irritability, excessive crying and vomiting did not increase following any of the three vitamin A doses. Only one infant in the vitamin A group had a bulging fontanelle 24 h after the third dose of supplement; no cases were seen after the first and second doses.
Discussion
Vitamin A supplementation to mothers in the postpartum period and to their infants with OPV at 6, 10 and 14 weeks Proportion with weight-for-height Z-score Impact of vitamin A on antibody response to OPV R Bahl et al improved antibody response to poliovirus type 1 and did not alter the response to poliovirus types 2 and 3. Our findings regarding the response to poliovirus types 2 and 3 are consistent with that of a recent Indonesian study, which reported that vitamin A did not affect antibody response to any of the polioviruses (Semba et al, 1999) . In a study with different but related study design, maternal vitamin A supplementation was shown to have no effect on antibody response to neonatal OPV administration (Bhaskaram & Balakrishna, 1998) . Our findings are, however, not in agreement with a study reporting reduced seroconversion to measles in infants with maternal antibodies (Semba et al, 1995) . It is notable that almost all our study infants had maternal antibodies at the time of immunization and supplementation.
The beneficial impact of vitamin A on antibody response is biologically plausible. Vitamin A has been shown to enhance T-helper cell numbers and cytokines that induce B cells to differentiate into greater number of immunoglobulin-secreting cells (Semba et al, 1993; Cantorna et al, 1995; Tokuyama & Tokuyama, 1996) . This effect is generally seen only for T-cell dependent antigens (Pasatiempo et al, 1990) . However, we have no clear explanation for why the beneficial effect was limited to poliovirus type 1. It is noteworthy that in the placebo group, the proportion of infants who had protective antibody titers following immunization was lower for poliovirus type 1 (71.2%) than that for type 2 (93.2%) or 3 (80.5%). In contrast, the Indonesian study had a substantially higher proportion of infants in the placebo group with protective antibody titers: 94, 99 and 96% for poliovirus types 1, 2 and 3 respectively (Semba et al, 1999) .
The lower antibody titers found in comparison to those of other studies (McBean et al, 1988; Faden et al, 1990 ; World Health Organization Collaborative Study Group on Oral Poliovirus Vaccine, 1995; Modlin et al, 1997) in children vaccinated with three doses of OPV are not due to low immunogenicity of the vaccine. The cold chain was rigorously maintained. It is conceivable that the lower antibody titers detected reflect the use of Salk polioviruses (type 1, Brunhilde; type 2, MEF; type 3, Sakett) for the titration of antibody by neutralization assay, while the infants were immunized with Sabin polioviruses. This aspect of the assay should not affect the differences in the neutralizing antibody titres between the group treated with vitamin A and the placebo group, and consequently the results of the study.
The findings of the present study confirm the safety of 60 mg RE vitamin A to the mother and 7.5 mg RE to the infant at 6, 10 and 14 weeks of age with regard to antibody response. This combined maternal and infant supplementation did not, however, have a beneficial impact on morbidity and mortality (WHO=CHD Immunization Linked Vitamin A Supplementation Study Group, 1998) .
